Quest Diagnostics rises after Q1 earnings beat and higher 2026 outlook

Quest Diagnostics (DGX) is up 4.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The stock appears to be moving higher after Quest reported first-quarter 2026 results that topped expectations and management raised full-year 2026 revenue and profit guidance. Investors likely viewed the combination of solid organic growth and a higher outlook as a signal that routine testing demand and execution remain resilient.

Details:

Quest reported Q1 2026 diluted EPS of $2.24 and adjusted diluted EPS of $2.50, with management highlighting year-over-year growth.

Quarterly net revenues were about $2.90 billion, up roughly 9% year over year, supported by strength in its diagnostic information services business.

Management lifted full-year 2026 guidance, including adjusted EPS of $10.63–$10.83 and revenue of $11.78–$11.90 billion (ranges provided with the earnings release).

The updated outlook came alongside commentary emphasizing continued demand for routine diagnostic testing and disciplined expense control.

Sources:

Quest Diagnostics (Newsroom), Associated Press, Reuters

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$DGX Insider Trading Activity

$DGX insiders have traded $DGX stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.

Here’s a breakdown of recent trading of $DGX stock by insiders over the last 6 months:

J. E. DAVIS (CEO and President) has made 0 purchases and 4 sales selling 65,093 shares for an estimated $12,714,959.
CATHERINE T. DOHERTY (EVP, Regional Businesses) has made 0 purchases and 8 sales selling 33,788 shares for an estimated $6,964,736.
PATRICK PLEWMAN (SVP for Diagnostic Services) has made 0 purchases and 4 sales selling 9,885 shares for an estimated $2,025,173.
MARK E DELANEY (SVP & Chief Commercial Officer) sold 7,946 shares for an estimated $1,488,683
MICHAEL E PREVOZNIK (SVP & General Counsel) has made 0 purchases and 3 sales selling 5,515 shares for an estimated $1,136,514.
KARTHIK KUPPUSAMY (SVP, Clinical Solutions) sold 2,628 shares for an estimated $538,372
GARY M PFEIFFER sold 1,482 shares for an estimated $270,316
VICKY B GREGG sold 1,250 shares for an estimated $239,700

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$DGX Hedge Fund Activity

We have seen 455 institutional investors add shares of $DGX stock to their portfolio, and 439 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,759,509 shares (-76.5%) from their portfolio in Q4 2025, for an estimated $478,857,596
WELLINGTON MANAGEMENT GROUP LLP removed 1,341,737 shares (-93.1%) from their portfolio in Q4 2025, for an estimated $232,831,621
EDGEPOINT INVESTMENT GROUP INC. added 811,320 shares (+95.5%) to their portfolio in Q4 2025, for an estimated $140,788,359
PRICE T ROWE ASSOCIATES INC /MD/ removed 708,833 shares (-10.1%) from their portfolio in Q4 2025, for an estimated $123,003,790
BLACKROCK, INC. removed 542,817 shares (-5.4%) from their portfolio in Q4 2025, for an estimated $94,195,034
RTW INVESTMENTS, LP removed 500,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $86,765,000
NEUBERGER BERMAN GROUP LLC removed 474,675 shares (-91.5%) from their portfolio in Q4 2025, for an estimated $82,370,352

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$DGX Government Contracts

We have seen $137,249,838 of award payments to $DGX over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

PRIMARY REFERENCE LABORATORY TESTING / COURIER SERVICES / PHLEBOTOMY: $8,400,000
VISN 7 REFERENCE LAB SERVICES: $8,250,000
REFERENCE LAB TESTING - OPTION 2: $3,375,189
REFERENCE LAB TESTING - ADD AND EXERCISE OPTION: $2,804,456
REFERENCE LAB TESTS: $2,748,684

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$DGX Congressional Stock Trading

Members of Congress have traded $DGX stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $DGX stock by members of Congress over the last 6 months:

REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 11/03.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$DGX Analyst Ratings

Wall Street analysts have issued reports on $DGX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Jefferies issued a "Buy" rating on 02/11/2026

To track analyst ratings and price targets for $DGX, check out Quiver Quantitative's $DGX forecast page.

$DGX Price Targets

Multiple analysts have issued price targets for $DGX recently. We have seen 8 analysts offer price targets for $DGX in the last 6 months, with a median target of $217.5.

Here are some recent targets:

Elizabeth Anderson from Evercore ISI Group set a target price of $210.0 on 04/08/2026
Ann Hynes from Mizuho set a target price of $235.0 on 02/12/2026
Tycho Peterson from Jefferies set a target price of $220.0 on 02/11/2026
Stephanie Davis from Barclays set a target price of $225.0 on 02/11/2026
Kevin Caliendo from UBS set a target price of $210.0 on 02/11/2026
David Macdonald from Truist Securities set a target price of $220.0 on 02/11/2026
Patrick Donnelly from Citigroup set a target price of $215.0 on 02/10/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.